Expression of BCL-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy

British Journal of Cancer

Volumn 74, Issue 1, 1996, Pages 78-85

  Van Slooten, H J ^a   Clahsen, P C ^a   Van Dierendonck, J H ^a   Duval, Ch ^b   Pallud, C ^c   Mandard, A M ^d   Delobelle Deroide, A ^e   Van De Velde, C J H ^a   Van De Vijver, M J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRE HENRI BECQUEREL   (France)

^c CENTRE RENÉ HUGUENIN   (France)

^d CENTRE FRANÇOIS BACLESSE   (France)

^e CENTRE OSCAR LAMBRET   (France)

Author keywords

Bcl 2; Breast cancer; Chemotherapy; Disease free survival; Drug resistance; p53

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MONOCLONAL ANTIBODY KI 67; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MITOSIS INDEX; MULTIVARIATE ANALYSIS; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR VOLUME;

EID: 0030015547     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.319     Document Type: Article

References (40)

1. BHARGAVA V, KELL DL, VAN DE RIJN M AND WARNKE RA. (1994). Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am. J. Pathol., 145, 535-539.
2. BOISE LH, GONÁLEZ-GARCÍA M, POSTEMA CE, DING L, LINDSTEN T, TURKA LA, MAO X, NUNEZ G AND THOMPSON CB. (1993). bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell, 74, 597-608.
3. CAMPOS L, ROUAULT JP, SABIDO O, ORIOL P, ROUBI N, VASSELON C, ARCHIMBAUD E, MAGAUD JP AND GUYOTAT D. (1993). High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood, 81, 3091-3096.
4. CASTLE VP, HEIDELBERGER KP, BROMBERG J, OU X, DOLE M AND NUNEZ G. (1993). Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am. J. Pathol., 143, 1543-1550.
5. CIVITAREALE D, LONIGRO R, SINCLAIR A AND DI LAURO R. (1989). A thyroid-specific nuclear protein essential for tissue-specific expression of the thyroglobulin promoter. EMBO J., 8, 2537-2542.
6. CLAHSEN PC, VAN DE VELDE CJH, DUVAL C, PALLUD C, MANDARD A-M, DELOBELLE-DEROIDE A, VAN DEN BROEK L, SAHMOUD T AND VAN DE VIJVER MJ. (1994a). Prognostic factors in premenopausal node-negative women with early breast cancer. Eur. J. Cancer, 30A (suppl. 2), S18.
7. CLAHSEN PC, VAN DE VELDE CJH, JULIEN JP, FLOIRAS JL AND MIGNOLET FY. (1994b). Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study. J. Clin. Oncol., 12, 1266-1271.
8. COX DR. (1972). Regression models and life-tables. J. R. Stat. Assoc., B34, 187-220.
9. DE JONG D, PRINS F, MASON D, REED J, VAN OMMEN G AND KLUIN P. (1994). Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer Res., 54, 256-260.
10. DEBBAS M AND WHITE E. (1993). Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev., 7, 546-554.
11. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP. (1992). Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet, 339, 1-15 71-85.
12. GASPARINI G, BARBARESCHI M, DOGLIONI C, DALLA PALMA P, MAURI FA, BORACCHI P, BEVILACQUA P, CAFFO O, MORELLI L, VERDERIO P, PEZZELLA F AND HARRIS AL. (1995). Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer, Clin. Cancer Res., 1, 189-198.
13. GEE JM, ROBERTSON JF, ELLIS IO, WILLSHER P, MCCLELLAND RA, HOYLE HB, KYME SR, FINLAY P, BLAMEY RW AND NICHOLSON RI. (1994). Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int. J. Cancer., 59, 619-628.
14. GOMPEL A, SABOURIN JC, MARTIN A, YANEVA H, AUDOUIN J, DECROIX Y AND POITOUT P. (1994). Bcl-2 expression in normal endometrium during the menstrual cycle. Am. J. Pathol., 144, 1195-1202.
15. HALDAR S, NEGRINI M, MONNE M, SABBIONI S AND CROCE CM. (1994). Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res., 54, 2095-2097.
16. HELLEMANS P, VAN DAM PA, WEYLER J, VAN OOSTEROM AT, BUYTAERT P AND VAN MARCK E. (1995). Prognostic value of bel-2 expression in invasive breast cancer. Br. J. Cancer, 72, 354-360.
17. HOCKENBERY DM, ZUTTER M, HICKEY W, NAHM M AND KORSMEYER SJ. (1991). BCL2 protein is topographically restricted in tissue characterized by apoptotic cell death. Proc. Natl Acad. Sci. USA, 88, 6961-6965.
18. ISOLA J, VISAKORPI T, HOLLI K AND KALLIONIEMI OP. (1992). Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J. Natl Cancer Inst., 85(14), 1109-1114.
19. JOENSUU H, PYLKKANEN L AND TOIKKANEN S. (1994). Bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol., 145, 1191-1198.
20. KAPLAN EL AND MEIER P. (1958). Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc., 53, 457-481.
21. KIEFER MC, BRAUER MJ, POWERS VC, WU JJ, UMANSKY SR, TOMEL LD AND BARR PJ. (1995). Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature, 374, 736-739.
22. LEEK RD, KAKLAMANIS L, PEZZELLA F, GATTER KC AND HARRIS AL. (1994). bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br. J. Cancer., 69, 135-139.
23. LIN EY, ORLOFSKY A, BERGER, MS AND PRYSTOWSKY MB. (1993). Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. J. Immunol., 151, 1979-1988.
24. LOWE SW, SCHMITT EM, SMITH SW, OSBORNE BA AND JACKS T. (1993). p53 is required for radiation-induced apoptosis in mouse thymocytes (see comments). Nature, 362(6423), 847-849.
25. LOWE SW, BODIS S, MCCLATCHEY A, REMINGTON L, RULEY HE, FISHER DE, HOUSMAN DE AND JACKS T. (1994). p53 status and the efficacy of cancer therapy in vivo. Science, 266, 807-810.
26. MANTEL N. (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50, 163-170.
27. MERRITT AJ, POTTEN CS, KEMP CJ, HICKMAN JA, BALMAIN A, LANE DP AND HALL PA. (1994). The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-defecient mice. Cancer Res., 54, 614-617.
28. MIYASHITA T, HARIGAI M, HANADA M AND REED JC. (1994). Identification of a p53-dependent negative response element in the bcl-2 Gene. Cancer Res., 54, 3131-3135.
29. OLTVAI ZN, MILLIMAN CL AND KORSMEYER SJ. (1993). Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74, 609-619.
30. PEZZELLA F, TURLEY H, KUZU I, TUNGEKAR MF, DUNNILL MS, PIERCE CB, HARRIS A, GATTER KC AND MASON DY. (1993). Bcl-2 protein in non-small-cell lung carcinoma. N. Engl. J. Med., 329, 690-694.
31. PILOTTI S, COLLINI P, RILKE F, CATTORETTI G, DEL BO R AND PIEROTTI MA. (1994). bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J. Pathol., 172, 337-342.
32. REED JC. (1994). Bcl-2 and the regulation of programmed cell death. (Review). J. Cell Biol., 124, 1-6.
33. REYNOLDS JE, YANG T, QIAN L, JENKINSON JD, ZHOU P, EASTMAN A AND CRAIG RW. (1994). Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-myc overexpression in Chinese hamster ovary cells. Cancer Res., 54, 6438-6352.
34. SABOURIN JC, MARTIN A, BARUCH J, TRUC JB, GOMPEL A AND POITOUT P. (1994). bcl-2 expression in normal breast tissue during the menstrual cycle. Int. J. Cancer, 59, 1-6.
35. SELVAKUMARAN M, LIN H.-K, MIYASHITA T, WANG HG, KRAJEWSKI S, REED JC, HOFFMAN B AND LIEBERMANN D. (1994). Immediate early up-reulation of bax expression by p53 but not TGF-B1: a paradigm for distinct apoptotic pathways. Oncogene, 9, 1791-1798.
36. SILVESTRINI R, VENERONI S, DAIDONE MG, BENINI E, BORACCHI P, MEZZETTI M, DI FRONZO G, RILKE F. AND VERONESI U. (1994). The bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl Cancer Inst., 86, 499-504.
37. VAN DE VIJVER MJ, PETERSE JL, MOOL WJ, et al. (1988). Neuprotein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N. Engl. J. Med., 319, 1239-1245.
38. L and Bcl-2, displaces Bax and promotes cell death. Cell. 80, 285-291.
39. YIN XM, OLTVAI ZN AND KORSMEYER SJ. (1995). Heterodimerization with Bax is required for Bcl-2 to repress cell death. Curr. Top. Microbiol. Immunol., 194, 331-338.
40. ZHU Y.-M, BRADBURY DA AND RUSSELL NH. (1994). Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells. Br. J. Cancer. 69, 468-472.